CANCER.
Information on current developments in both regular and alternative or complementary treatments for cancer types and resources at all stages. We have basically all articles and information put in alphabetical order, scroll in left column in alphabetical list.
Experiences of cancer patients with complementary approaches can be found by experience stories and there are also some videos of experiences of cancer patients to see. To click on video button top left . Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.
Car vaccination in colon cancer. Oncovax gives significantly better result on survival, survival time and time to relapse in patients with darmkanker stadum II. However, no significant difference in colon cancer stage III. Unfortunately in 2007, producer of Intracel, Oncovax and hence Oncovax is declared bankrupt disappeared as a treatment for colon cancer. Article update 10 may 2012
7 may 2012: although so Oncovax is no longer available turns out to be a form of auto vaccination of colon cancer is indeed to be tested and applied. Click here for article: Immunotherapies: Oncophage (R) (HSPPC-96), made from own tumor cells allows for remarkable results with colon cancer.
October 31, 2010: Intracel In 2009, the company is declared bankrupt. The patent Oncovax which it is apparently not available in the Netherlands had more. At least I cannot find it anywhere. Click here for court declaration of bankruptcy report. Meanwhile showed that the authorisation is not transferable to a third party. If the laboratory in Emmen in unmodified form will be continued by a third party, however, is the expectation, that third of the Dutch Government also will get a licence to use the medication in patients OncoVax . OncoVax medication is primarily used for patients in Switzerland, this because those patients would have sufficient financial resources for the treatment with OncoVax. In Netherlands and in other countries is no (partial) reimbursement of the costs of OncoVax village by health insurers. The bankrupt companies of the Swiss Government a im-and export authorization to send to and from Switzerland of tissue. It is not yet known whether that licence is transferable
A very sad development.
Update 25 July 2009: we sometimes get questions about bowel cancer immunotherapies with dendritic cell therapy or in colon cancer. I think it is good to read all information below again placed in 2005 but I still relevant. Tell oncologists about the developments. darmkankerpatienten never and evidence of car vaccination in colon cancer. I do not know why but you can still freeze your fresh in tumorweerfsel of course. If only to use it later. Be careful that the fresh tumor tissue both surgeons who perform surgery to obtain via the is frozen and stored correctly.
14 March 2005: source: Vaccine. 2005 Mar 18; 23 (17-18): 2379-87.
WARNING: who wants to come into consideration for Oncovax operation or treatment should first advance to first own tumor tissue deep freezing (-70% c.) or direct own tumor tissue to send to producer of so that there is a vaccine of Oncovax can be made. ASK YOUR ONCOOOG ALREADY SPECIFICALLY ACCOMPANIED BY SUCH ADVANCE TO FIRST TREATMENT.
The vaccine significantly longer survival, more definitive proves Oncovax overlevingen and longer time to relapse in patients after operation darmkanker II new stage, said a Dutch randomized phase III study in multiple hospitals. Based on a BCG vaccine bacillus Callmette-Guerin (BCG) created, brand name were OncoVAX ((R), own tumor cells-autologous cells-entered after operation in patients darmkanker, both in stage II and III. However in patients with stage II was, however, a significantly better result posted, however, in colon cancer stage III. 57.1% less chance after operation on a relapse by Oncovax is not wrong in this vulnerable group of cancer patients. The strange thing is that Oncovax already has proven to give significantly better results for much longer in colon cancer. Now We ask ourselves to what extent the publication of this study has to do with the publicity about TACE and LITT treatments where patients now for Germany to go Dutch. It is noteworthy that this study, which also figures in 2001 and last year were already vijrgegeven, now is published at this time, especially when you see that a.o. Prof. Dr. Pinedo to this study has worked all these years. And in the silence and stop opposite patients for years but VU about this possibility. A great shame companies Here the abstract of the study as described in Pubmed, but also read further information under Oncovax under this series of articles under car vaccination and bowel cancer
Autologous tumor cell-BCG vaccine immunotherapie with in patients with colon cancer: a prospective study of medical and economic benefits.
Uyl-the Great CA, MG, Hanna Verboom Vermorken JB Jr., P, great MT, GJ, Meijer CJ, Pinedo HM Bonsel.
Department of Health Care Polity and Management, Institute for Medical Technology Assessment, Erasmus Medical Center Rotterdam, The Netherlands.
We have completed a multicenter, randomized controlled phase III clinical trial in Stages II and III colon cancer patients with active (ASI) using autologous tumor cells immunotherapie specific with an immunomodulating adjuvant bacillus Callmette-Guerin (BCG) vaccine (OncoVAX ((R))) in an adjuvant setting. In this study, patients were randomized to receive either OncoVAX ((R)) therapy or no therapy after surgical resection of the primary tumor and stratified by stage of disease. Since the biologicessence of the effective tumor immunotherapie is the presence in the vaccine or a minimum number of autologous tumor cells, metabolically active, viable, the processing of the vaccine product, occurred within 48 h after surgery. Analysis of prognostic benefit in the pivotal phase III trial, with a 5.8 year median follow-up, showed that a beneficial effect or OncoVAX ((R)) is statistically significant for all endpoints including recurrence-free interval, overall survival, and recurrence-free survival in Stage II colon cancer patients. Surgery alone cures approximately 65% or Stage II (Dukes B (2), B (3)) colon cancer patients. In the remaining patients, OncoVAX ((R)) in an adjuvant setting, significantly prolongs recurrence-free interval (57.1% relative risk reduction) and significantly improves 5-year overall survival and recurrence-free survival. No statistically significant prognostic benefits were achieved in Stage III (Duke's C (1)-C (3)) patients. A health economics assessment was performed on these results in Stage II colon cancer patients using disease-free survival and overall survival (for the entire intent-to-treat population). Cost-effectiveness, cost utility and sensitivity analysis were applied with, cost of life years, recurrence-free life years and quality adjusted life years (QALYs) as the primary endpoints to this analysis. The perspective of the economic analysis was the current direct medical cost established by the health care providers. The introduction of new technologies often leads to additional costs. This report verified that the use of OncoVAX ((R)) for patients with Stage II colon cancer not only has significant prognostic benefit and positive clinical outcomes, but also showed that OncoVAX ((R)) therapy yields impressive benefits health economics. PMID: 15755632 [PubMed-in process]
